Buprenorphine (CAM2038) trial for the treatment of opioid dependent patients with chronic pain.
Phase of Trial: Phase II
Latest Information Update: 17 May 2016
At a glance
- Drugs Buprenorphine (Primary)
- Indications Pain
- Focus Pharmacokinetics
- 17 May 2016 According to a Camurus media release, the company anticipates the results of this trial in the fourth quarter of 2016.
- 22 Feb 2016 According to Braeburn Pharmaceuticals media release, first patients have been dosed in this trial.
- 22 Feb 2016 According to Braeburn Pharmaceuticals media release, status changed from planning to recruiting.